Payment overview · 2025
General Payments
$764.38
36 reported records · 8 companies
Healthcare provider profile · identity verified
Michael G Holman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KOSCIUSKO, MS · NPI 1073576070
Verified facts
What the public records show
CMS Open Payments records show Michael G Holman, MD received $764.38 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $282.88 | 37.0% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $181.19 | 23.7% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $91.50 | 12.0% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.79 | 8.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.00 | 7.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.83 | 4.2% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $27.87 | 3.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.32 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $764.38 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $181.19 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $143.78 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $143.78 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $123.05 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $118.10 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $60.00 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.04 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.83 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.89 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| BOOSTRIX Normalized: boostrix |
Biological | GlaxoSmithKline, LLC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 202 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 79 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
110 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 446 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 394 | 101 |
| Omeprazole | Omeprazole | 318 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 287 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 282 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 267 | 69 |
| Gabapentin | Gabapentin | 256 | 69 |
| Furosemide | Furosemide | 217 | 71 |
| Potassium Chloride | Potassium Chloride | 216 | 53 |
| Metformin Hcl | Metformin Hcl | 210 | 51 |
| Eliquis | Apixaban | 202 | 28 |
| Losartan Potassium | Losartan Potassium | 202 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 171 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 162 | 38 |
| Lisinopril | Lisinopril | 160 | 46 |
| Carvedilol | Carvedilol | 154 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 154 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 144 | 38 |
| Famotidine | Famotidine | 138 | 33 |
| Meloxicam | Meloxicam | 134 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 38 |
| Metformin Hcl Er | Metformin Hcl | 130 | 31 |
| Valsartan | Valsartan | 129 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 35 |
| Simvastatin | Simvastatin | 126 | 33 |
| Chlorthalidone | Chlorthalidone | 118 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 42 |
| Synthroid | Levothyroxine Sodium | 110 | 19 |
| Spironolactone | Spironolactone | 104 | 31 |
| Aripiprazole | Aripiprazole | 103 | 13 |
| Allopurinol | Allopurinol | 99 | 27 |
| Pregabalin | Pregabalin | 97 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 90 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 20 |
| Donepezil Hcl | Donepezil Hcl | 89 | 27 |
| Tramadol Hcl | Tramadol Hcl | 88 | 22 |
| Trazodone Hcl | Trazodone Hcl | 88 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 86 | 66 |
| Ozempic | Semaglutide | 86 | 22 |
| Trulicity | Dulaglutide | 85 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 84 | 19 |
| Prednisone | Prednisone | 83 | 53 |
| Montelukast Sodium | Montelukast Sodium | 82 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 26 |
| Farxiga | Dapagliflozin Propanediol | 79 | 22 |
| Risperidone | Risperidone | 79 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 79 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 20 |
| Propranolol Hcl | Propranolol Hcl | 73 | 12 |
| Levetiracetam | Levetiracetam | 71 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 71 | 16 |
| Clonazepam | Clonazepam | 70 | suppressed |
| Myrbetriq | Mirabegron | 68 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 66 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 18 |
| Meclizine Hcl | Meclizine Hcl | 65 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 12 |
| Jardiance | Empagliflozin | 64 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 25 |
| Ibuprofen | Ibuprofen | 62 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 15 |
| Irbesartan | Irbesartan | 61 | suppressed |
| Mounjaro | Tirzepatide | 61 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 58 | 17 |
| Celecoxib | Celecoxib | 57 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | suppressed |
| Colchicine | Colchicine | 53 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 19 |
| Glimepiride | Glimepiride | 52 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 12 |
| Lactulose | Lactulose | 44 | 14 |
| Linzess | Linaclotide | 44 | suppressed |
| Naproxen | Naproxen | 42 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | 13 |
| Alendronate Sodium | Alendronate Sodium | 40 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Lorazepam | Lorazepam | 40 | suppressed |
| Baclofen | Baclofen | 39 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 38 | 13 |
| Scopolamine | Scopolamine | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 11 |
| Topiramate | Topiramate | 34 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 15 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 11 |
| Finasteride | Finasteride | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 19 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Metolazone | Metolazone | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Fluocinonide | Fluocinonide | 27 | 12 |
| Atenolol | Atenolol | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 19 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Clotrimazole | Clotrimazole | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 18 |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Tradjenta | Linagliptin | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Haloperidol | Haloperidol | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Enpresse | Levonorgestrel/Ethin.Estradiol | 13 | suppressed |
| Felbamate | Felbamate | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Generlac | Lactulose | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Mupirocin | Mupirocin | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $764.38 · 36 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BOOSTRIX, BREZTRI, CAPLYTA, COMIRNATY, CREON, ELIQUIS, FARXIGA, LINZESS, NURTEC ODT, Ozempic, PREVNAR 20, QUTENZA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error